Mostrar el registro sencillo del ítem

dc.contributor.author
Flor, Noelia  
dc.contributor.author
García, María Inés  
dc.contributor.author
Molineri, Ana Inés  
dc.contributor.author
Bottasso, Oscar Adelmo  
dc.contributor.author
Diez, Cristina Noemí  
dc.contributor.author
Veaute, Carolina Melania Isabel  
dc.date.available
2024-02-06T13:34:50Z  
dc.date.issued
2023-11  
dc.identifier.citation
Flor, Noelia; García, María Inés; Molineri, Ana Inés; Bottasso, Oscar Adelmo; Diez, Cristina Noemí; et al.; Antibodies to SARS-CoV2 induced by vaccination and infection correlate with protection against the infection; Elsevier; Vaccine; 41; 48; 11-2023; 7206-7211  
dc.identifier.issn
0264-410X  
dc.identifier.uri
http://hdl.handle.net/11336/225937  
dc.description.abstract
The COVID-19 pandemic remained worldwide for almost three years, but little is known about the dynamics of humoral immune response to the third dose over time and its protection from infection. Our aim was to assess the humoral immune response after the third dose of the different vaccines administered to SARS-CoV-2 naive and previously infected individuals, and its correlation with protection in an academic community. For each person studied (185), three blood samples were taken between December 2021 and July 2022, one month apart. Anti-S antibodies were quantified by ELISA, while anti-N antibody levels were determined by ECLIA. Most of the participants had received two doses of viral vector-based, mRNA-based and virus-inactivated vaccines. Although anti-N antibody levels revealed that 80% of the individuals had been exposed to the virus before or during the study, only 42% reported having been diagnosed. When anti-S IgG levels were measured 3–5 months after the second dose of any vaccine, they were higher in those previously infected individuals. The same results were observed for anti-N IgG levels in those who received 2 doses of the virus-inactivated vaccine. When analyzing the dynamics of anti-S antibodies we observed that, although positive IgG antibody levels were detected 5–6 months after the second dose administration, those observed 30–60 days after the third dose were significantly higher and remained so for at least 8 months. Higher levels of anti-S IgG antibodies at the first sampling were associated with a lower incidence of subsequent infection. The same association was seen in people who received the booster compared with those who received two doses. This study provides further evidence that anti-S IgG antibodies remained at high levels over time, and both anti-S levels and the third dose of anti-SARS-CoV-2 vaccine correlate with protection against the infection. It also shows that infection acts as a booster of immunization, increasing levels of both anti-N and anti-S IgG.  
dc.format
application/pdf  
dc.language.iso
eng  
dc.publisher
Elsevier  
dc.rights
info:eu-repo/semantics/restrictedAccess  
dc.rights.uri
https://creativecommons.org/licenses/by-nc-nd/2.5/ar/  
dc.subject
COVID-19  
dc.subject
IMMUNITY  
dc.subject
SARS-COV-2  
dc.subject
SEROSURVEILLANCE  
dc.subject
VACCINE  
dc.subject.classification
Otros Tópicos Biológicos  
dc.subject.classification
Ciencias Biológicas  
dc.subject.classification
CIENCIAS NATURALES Y EXACTAS  
dc.title
Antibodies to SARS-CoV2 induced by vaccination and infection correlate with protection against the infection  
dc.type
info:eu-repo/semantics/article  
dc.type
info:ar-repo/semantics/artículo  
dc.type
info:eu-repo/semantics/publishedVersion  
dc.date.updated
2024-02-02T15:31:24Z  
dc.journal.volume
41  
dc.journal.number
48  
dc.journal.pagination
7206-7211  
dc.journal.pais
Países Bajos  
dc.journal.ciudad
Amsterdam  
dc.description.fil
Fil: Flor, Noelia. Universidad Nacional del Litoral. Facultad de Bioquimica y Ciencias Biologicas. Laboratorio de Inmunologia Experimental.; Argentina  
dc.description.fil
Fil: García, María Inés. Universidad Nacional del Litoral. Facultad de Bioquimica y Ciencias Biologicas. Laboratorio de Inmunologia Experimental.; Argentina  
dc.description.fil
Fil: Molineri, Ana Inés. Consejo Nacional de Investigaciones Cientificas y Tecnicas. Centro Cientifico Tecnologico Conicet - Santa Fe. Instituto de Investigacion de la Cadena Lactea. - Instituto Nacional de Tecnologia Agropecuaria. Centro Regional Santa Fe. Estacion Experimental Agropecuaria Rafaela. Instituto de Investigacion de la Cadena Lactea.; Argentina  
dc.description.fil
Fil: Bottasso, Oscar Adelmo. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Rosario. Instituto de Inmunología Clinica y Experimental de Rosario. Universidad Nacional de Rosario. Facultad de Ciencias Médicas. Instituto de Inmunología Clinica y Experimental de Rosario; Argentina  
dc.description.fil
Fil: Diez, Cristina Noemí. Universidad Nacional del Litoral. Facultad de Bioquímica y Ciencias Biológicas; Argentina  
dc.description.fil
Fil: Veaute, Carolina Melania Isabel. Universidad Nacional del Litoral. Facultad de Bioquímica y Ciencias Biológicas; Argentina. Universidad Nacional del Litoral. Facultad de Bioquimica y Ciencias Biologicas. Laboratorio de Inmunologia Experimental.; Argentina  
dc.journal.title
Vaccine  
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/https://www.sciencedirect.com/science/article/pii/S0264410X23012215  
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/https://doi.org/10.1016/j.vaccine.2023.10.038